{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:06:08Z","timestamp":1776168368785,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematopathol"],"DOI":"10.1007\/s12308-026-00692-8","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:26:07Z","timestamp":1776165967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of combined digital PCR and multiparametric flow cytometry monitoring MRD in non-transplant acute myeloid leukemia"],"prefix":"10.1007","volume":"19","author":[{"given":"Shaojie","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"12","key":"692_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"issue":"5","key":"692_CR2","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM (2025) Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol 100(5):860\u2013891","journal-title":"Am J Hematol"},{"issue":"26","key":"692_CR3","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ et al (2021) 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 138(26):2753\u20132767","journal-title":"Blood"},{"issue":"1","key":"692_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05114-w","volume":"22","author":"W Chen","year":"2024","unstructured":"Chen W, Huang J, Zhao Y et al (2024) Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML\/MDS: a multicenter retrospective study. J Transl Med 22(1):410","journal-title":"J Transl Med"},{"key":"692_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01271","volume":"10","author":"J van Dongen","year":"2019","unstructured":"van Dongen J, van der Burg M, Kalina T et al (2019) Euroflow-based flowcytometric diagnostic screening and classification of primary immunodeficiencies of the lymphoid system. Front Immunol 10:1271","journal-title":"Front Immunol"},{"issue":"5","key":"692_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s12185-022-03402-z","volume":"116","author":"X Chen","year":"2022","unstructured":"Chen X, Liu L, Zhang A et al (2022) Droplet digital PCR for genetic mutations monitoring predicts relapse risk in pediatric acute myeloid leukemia. Int J Hematol 116(5):669\u2013677","journal-title":"Int J Hematol"},{"issue":"6","key":"692_CR7","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jmoldx.2022.03.004","volume":"24","author":"Y Lu","year":"2022","unstructured":"Lu Y, Li Z, Lim EH, Huan PT, Kham S, Yeoh AE (2022) Digital PCR for minimal residual disease quantitation using immunoglobulin\/T-cell receptor gene rearrangements in acute lymphoblastic leukemia: a proposed analytic algorithm. J Mol Diagn 24(6):655\u2013665","journal-title":"J Mol Diagn"},{"issue":"9","key":"692_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093141","volume":"21","author":"N Coccaro","year":"2020","unstructured":"Coccaro N, Tota G, Anelli L, Zagaria A, Specchia G, Albano F (2020) Digital PCR: a reliable tool for analyzing and monitoring hematologic malignancies. Int J Mol Sci 21(9):3141","journal-title":"Int J Mol Sci"},{"issue":"6","key":"692_CR9","first-page":"1766","volume":"109","author":"AC Winters","year":"2024","unstructured":"Winters AC, Minhajuddin M, Stevens BM et al (2024) Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax\/azacitidine. Haematologica 109(6):1766\u20131778","journal-title":"Haematologica"},{"issue":"12","key":"692_CR10","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, Zhou S, Fu C et al (2020) Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol 6(12):1890\u20131899","journal-title":"JAMA Oncol"},{"issue":"Supplement 1","key":"692_CR11","doi-asserted-by":"publisher","first-page":"6274","DOI":"10.1182\/blood-2022-167856","volume":"140","author":"M Mohd","year":"2022","unstructured":"Mohd M, Mohd M, Brett M et al (2022) Molecular MRD by digital PCR is prognostic of outcomes in AML patients on intensive and non-intensive treatment regimens. Blood 140(Supplement 1):6274\u20136275","journal-title":"Blood"},{"issue":"4","key":"692_CR12","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/blood.2023021579","volume":"143","author":"J Othman","year":"2024","unstructured":"Othman J, Tiong IS, O\u2019Nions J et al (2024) Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy. Blood 143(4):336\u2013341","journal-title":"Blood"},{"issue":"10","key":"692_CR13","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s00277-018-3373-y","volume":"97","author":"M Bill","year":"2018","unstructured":"Bill M, Grimm J, Jentzsch M et al (2018) Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients. Ann Hematol 97(10):1757\u20131765","journal-title":"Ann Hematol"},{"issue":"19","key":"692_CR14","doi-asserted-by":"publisher","first-page":"4860","DOI":"10.1182\/bloodadvances.2025016726","volume":"9","author":"EL Boertjes","year":"2025","unstructured":"Boertjes EL, Vonk CM, Kavelaars FG et al (2025) Utility of IDH1\/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia. Blood Adv 9(19):4860\u20134869","journal-title":"Blood Adv"},{"key":"692_CR15","doi-asserted-by":"crossref","unstructured":"Levis MJ, Erba HP, Montesinos P, et al (2026) FLT3-ITD measurable residual disease from the QuANTUM First trial. Blood Adv 10(3): 917\u2013928","DOI":"10.1182\/bloodadvances.2025016444"},{"issue":"12","key":"692_CR16","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1200\/JCO.19.03011","volume":"38","author":"CS Hourigan","year":"2020","unstructured":"Hourigan CS, Dillon LW, Gui G et al (2020) Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol 38(12):1273\u20131283","journal-title":"J Clin Oncol"},{"issue":"5","key":"692_CR17","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41588-023-01376-0","volume":"55","author":"JH Bae","year":"2023","unstructured":"Bae JH, Liu R, Roberts E et al (2023) Single duplex DNA sequencing with CODEC detects mutations with high sensitivity. Nat Genet 55(5):871\u2013879","journal-title":"Nat Genet"},{"issue":"6","key":"692_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12061305","volume":"12","author":"S Galimberti","year":"2022","unstructured":"Galimberti S, Balducci S, Guerrini F, Del Re M, Cacciola R (2022) Digital droplet PCR in hematologic malignancies: a new useful molecular tool. Diagnostics 12(6):1305","journal-title":"Diagnostics"},{"issue":"15","key":"692_CR19","first-page":"762","volume":"52","author":"S Ye","year":"2025","unstructured":"Ye S, Guo H, Xu J, Su X, Wang L, Zhao S, Wang J, Xue H (2025) Monitoring measurable residual disease with multigene mutations ddPCR combined with multiparametric flow cytometry to predict relapse risk in patients with acute myeloid leukemia. Chin J Clin Oncol 52(15):762\u2013768","journal-title":"Chin J Clin Oncol"}],"container-title":["Journal of Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-026-00692-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12308-026-00692-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-026-00692-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:26:10Z","timestamp":1776165970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12308-026-00692-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["692"],"URL":"https:\/\/doi.org\/10.1007\/s12308-026-00692-8","relation":{},"ISSN":["1865-5785"],"issn-type":[{"value":"1865-5785","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was conducted in accordance with the Declaration of Helsinki. The protocol for\u00a0the present study was approved by the Institutional Review Boards of the affiliated hospital of Hebei\u00a0University (approval no. HDFYLL-KY-2024-133). All patients signed written informed consent for\u00a0this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"16"}}